-
12/18/2012
PAION received milestone payment of USD 3 million from Ono Pharmaceutical due to enrolment of first patient into the Phase II/III study with Remimazolam in Japan
-
11/05/2012
PAION AG: New Supervisory Board Member appointed
-
11/05/2012
PAION's Partner ONO Pharmaceutical announced today initiation of a Phase II/III StudY with short-acting anaesthetic/sedative Remimazolam (ONO's Development code: ONO-2745) in Japan
-
08/08/2012
PAION AG reports financial results for the first half year 2012
-
08/08/2012
PAION realizes first step of strategic realignment: Purchase of Remifentanil distribution rights for Germany
-
08/01/2012
Article about Remimazolam has been chosen as article of the month by Anesthesia & Analgesia (A&A)
-
07/18/2012
PAION AG grants license to YICHANG Humanwell for Remimazolam in China
-
07/09/2012
Preclinical Efficacy of Solulin in radiation injury confirmed in US/german Research collaboration and published in “Nature Medicine“
-
07/02/2012
PAION Deutschland GmbH receives a Grant worth EUR 0.7 million from the Federal Ministry of Education and Reserach (BMBF) for research into the potential of thrombomodulin - mutants
-
05/14/2012
Results of Phase II Study of Remimazolam (ONO-2745/CNS 7056), a Short-acting General Anesthetic
-
04/17/2012
PAION receives Euro 2.1 Million through the sale of Desmoteplase by completion of data and know-how transfer from H. Lundbeck A/
-
03/22/2012
PAION signed exclusive option agreement with Yichang for Remimazolam in China
-
03/14/2012
PAION AG reports financial results for the full year 2011
-
02/28/2012
PAION Receives Euro 20 Million for Sale of Remaining Desmoteplase Rights to H. Lundbeck A/S